Drug Topics
APRIL 1, 2024
It’s important that pharmacists continuously revise their counseling as new information about substances such as xylazine, levamisole, and phenacetin emerges, said Anita Jacobson at this year’s American Pharmacists Association Annual Meeting & Exposition.
Drug Topics
APRIL 1, 2024
In comparison with the traditional volume-based pharmacy model, the membership model decreases financial barriers while increasing customer-pharmacist relationships.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 4, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S. needs to stay on top in biotech.
Drug Topics
APRIL 1, 2024
According to Anita Jacobson, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
APRIL 3, 2024
As artificial intelligence rapidly advances in healthcare, the industry is grappling with how to evaluate AI models for accuracy and performance and monitor the technology for any downstream advers | The healthcare industry is grappling with how to evaluate AI models for accuracy and performance and monitor the technology for any downstream adverse outcomes.
Pharmacy Times
APRIL 1, 2024
Tirzepatide is currently approved for management of type 2 diabetes, improving glucose control, facilitating weight loss, and improving cardiovascular disease outcomes.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
APRIL 5, 2024
Eric Fromhart, co-founder and chief growth officer at Aventi Health, talked about the importance of the 340B drug pricing program at the 2024 AAP annual conference.
Fierce Healthcare
APRIL 1, 2024
Insurers will feel resentful Monday as the feds opted to not reverse its decision to decrease Medicare Advantage benchmark payments by 0.16%, the Centers for Medicare and Medicaid announced. | CMS is not deviating from its January proposal to modestly rein in Medicare Advantage. Benchmark payments will still decrease 0.16% but the feds expect it will still pay up to $600 billion in payments to plans in 2025.
Pharmacy Times
APRIL 1, 2024
Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.
STAT
APRIL 5, 2024
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows previously had been seen to be susceptible to human flu viruses , and could be experimentally infected with H5 in a lab, the absence of cow involvement until now in H5’s nearly 30-year history lulled scientists into thinking the species was outside the virus’s remit.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
APRIL 5, 2024
With drug price negotiations for 10 drugs through the Inflation Reduction Act (IRA) set to take effect in 2026, researchers simulated the extent of Medicare savings.
Fierce Healthcare
APRIL 5, 2024
Centers for Medicare & Medicaid Services finalized a host of actions ranging from broker compensation, health equity, mental health, supplemental benefits and biosimiliars, in the Contract Year | Medicare Advantage plans will need to adjust to new star ratings requirements, industry watchers warned following a final rule on Thursday.
Pharmacy Times
APRIL 1, 2024
Stephanie Ashraf, MD, offered clinical experience in managing insomnia at the American Medical Women’s Association (AMWA) 2024 Annual Meeting.
STAT
APRIL 5, 2024
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or two, and their human’s happiness. But increasingly, their own happiness is the topic of concern in veterinarian offices, dog parks, and internet forums. Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets’ separation anxiety, socialization fears, biting habits, or other
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
APRIL 5, 2024
In 4 posters presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024, researchers addressed pharmacists’ role in managing patients’ anticancer medications.
Fierce Healthcare
APRIL 5, 2024
Four in 10 therapists are planning to raise their fees in 2024, a new survey has found. | In last year’s report, 64% of therapists said they were planning to raise their fees in 2023. Yet only a third did, which could be explained by therapists' desire to remain accessible to patients.
Pharmacy Times
APRIL 5, 2024
Greg Baker, CEO of AffirmedRx, discusses the DRUG Act legislation and its potential impact on curbing rising drug costs through PBM reform.
STAT
APRIL 4, 2024
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by the Food and Drug Administration in 2022 , based on data that showed a modest slowing of disease progression. The approval was contentious — regulators initially advised Amylyx not to file for approval until it had conducted another test, but ultimately cleared the drug.
Drug Topics
APRIL 3, 2024
It can be hard to look away from a once in a lifetime total eclipse, but it’s important to understand the risks that come with viewing.
Fierce Healthcare
APRIL 2, 2024
Big-box retailer Costco is expanding its reach into healthcare services with a new weight loss program for members. | Big-box retailer Costco is expanding its reach into healthcare services with a new weight loss program for members.
Fierce Pharma
APRIL 5, 2024
After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers Squibb’s CAR-T therapy Abecma into the earlier treatment of multiple myeloma. | After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers’ CAR-T therapy Abecma into the earlier treatment of multiple myeloma.
STAT
APRIL 4, 2024
It began with injecting monkeys with sewage to see if they developed polio. Building off that early polio work from the 1940s, researchers from the Baylor College of Medicine analyzed public wastewater and showed they could detect over 450 disease-causing viruses. Their study demonstrating the power of sewage as an early-warning system for outbreaks won the 2024 STAT Madness popular vote.
Drug Topics
APRIL 3, 2024
This year’s conference, which is being held April 4 to 6 in San Diego, California, features talks from industry experts on developments in the pharmacy field, actionable skills, and informative CE sessions.
Fierce Healthcare
APRIL 5, 2024
Amwell could find itself dropped from the New York Stock Exchange if it isn’t able to turn its share prices around. | The telehealth giant's shares have closed below $1 on average for the past 30 days. The company said it would address the deficiency by effecting a reverse stock split.
PharmaVoice
APRIL 3, 2024
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
Drug Topics
APRIL 2, 2024
Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.
Fierce Healthcare
APRIL 4, 2024
Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic solution. | Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic soultion.
Fierce Pharma
APRIL 1, 2024
While the market for COVID-19 vaccines has been shrinking lately, an investigation into text messages between Pfizer CEO Albert Bourla and the European Commission’s President Ursula von der Leyen r | The European Public Prosecutor’s Office (EPPO) took over the investigation into COVID vaccine negotiations between the European Commission's president and Pfizer's CEO Albert Bourla, Politico reports.
STAT
APRIL 5, 2024
Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second major deal in the cardiovascular space in two years, following its 2022 purchase of Abiomed for $16.6 billion. Shockwave Medical’s device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves — a treatment called intravascular lithotripsy.
Drug Topics
APRIL 4, 2024
The antibiotic was approved to treat Staphylococcus aureas bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
Pharmacy Times
APRIL 5, 2024
These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.
Fierce Pharma
APRIL 2, 2024
Amid steadily increasing demand for Eli Lilly’s popular diabetes med Mounjaro, it appears patients on multiple dose strengths may have to wait even longer than anticipated to re-up on supply. | Four dose strengths are now expected to be in short supply through April, according to the FDA. The agency previously expected the squeeze to let up at the end of March.
STAT
APRIL 3, 2024
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease. In a Phase 2 trial, patients with early Parkinson’s disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year,
Expert insights. Personalized for you.
212 
Let's personalize your content